Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Ho... by Minoru Kanaya, Masahiro Onozawa, Toshihiro Matsukawa, Naoki Miyashita, Fumiaki Fujii, Shota Yoshida, Jun Nagai, Masayuki Aiba, Daisuke Hidaka, Junichi Hashiguchi, Hajime Senjo, Tetsuyuki Igarashi, Masahiro Chiba, Satoshi Yamamoto, Taku Shimizu, Takashi Ishio, Shota Yokoyama, Ko Ebata, Satoshi Iyama, Tatsuo Oyake, Takeshi Kondo, Takanori Teshima

Get full text